{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:38:14Z","timestamp":1785245894689,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100003395","name":"Skin Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008130","name":"Helsinn Therapeutics US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clml.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T02:39:19Z","timestamp":1645670359000},"page":"581-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Response to Chlormethine\/Mechlorethamine gel Maintenance Treatment Regimen in Patients With Mycosis Fungoides: A Single-center Retrospective Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0463-0395","authenticated-orcid":false,"given":"Emily","family":"Correia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Krishnasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayson G.","family":"Suriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyfettin Onder","family":"Alpdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-8689","authenticated-orcid":false,"given":"Neda","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.02.002_bib0002","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.annder.2018.11.012","article-title":"Primary skin lymphomas: current therapy","volume":"146","author":"Dereure","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clml.2022.02.002_bib0003","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.02.002_bib0004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome - Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.02.002_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21037\/cco.2018.10.01","article-title":"Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment","volume":"8","author":"Jennings","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.clml.2022.02.002_bib0006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2020.10.007","article-title":"Maintenance therapy in patients with mycosis fungoides or Sezary syndrome: a neglected topic","volume":"142","author":"Stadler","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.02.002_bib0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/DDDT.S137106","article-title":"Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data","volume":"12","author":"Liner","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clml.2022.02.002_bib0008","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1007\/s12325-021-01721-x","article-title":"Chlormethine gel in combination with other therapies in the treatment of patients with mycosis fungoides cutaneous T cell lymphoma: three case reports","volume":"38","author":"Lampadaki","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2022.02.002_bib0009","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. PMID: 31643176."},{"key":"10.1016\/j.clml.2022.02.002_bib0010","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/CMAR.S138661","article-title":"Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel","volume":"11","author":"Denis","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2022.02.002_bib0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2022.02.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.12.009","article-title":"Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"141","author":"Querfeld","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2022.02.002_bib0013","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jdcr.2020.05.031","article-title":"Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis","volume":"6","author":"Gilmore","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clml.2022.02.002_bib0014","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","article-title":"The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clml.2022.02.002_bib0015","series-title":"Presented at the 4th World Congress of Cutaneous Lymphomas","article-title":"Incidence and types of contact dermatitis after chlormethine gel treatment in patients with mycosis fungoides-type cutaneous T-cell lymphoma: The MIDAS study","author":"Gilmore","year":"2020"},{"key":"10.1016\/j.clml.2022.02.002_bib0016","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3911","article-title":"Management of mycosis fungoides with topical chlormethine\/mechlorethamine gel: a Columbia university cutaneous lymphoma center experience","volume":"101","author":"Garcia-Saleem","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clml.2022.02.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1007\/s13555-021-00539-3","article-title":"Chlormethine Gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous t-cell lymphoma: a narrative review and international experience","author":"Geskin","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.clml.2022.02.002_bib0018","first-page":"1","article-title":"Real-life experience with chlormethine gel for early-stage mycosis fungoides with emphasis on types and management of cutaneous side-effects","author":"Prag Naveh","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clml.2022.02.002_bib0019","article-title":"Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: a phase 2 extension study","author":"Querfeld","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2022.02.002_bib0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clml.2022.02.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2021.04.023","article-title":"83JAK-STAT inhibition mediates romidepsin and mechlorethamine synergism in cutaneous T-cell lymphoma","author":"Cortes","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2022.02.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2021.04.023","article-title":"Jak-STAT inhibition mediates romidepsin and mechlorethamine synergism in cutaneous T-cell lymphoma","author":"Cortes","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2022.02.002_bib0023","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3109\/10428194.2014.995649","article-title":"Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma","volume":"56","author":"Dulmage","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.02.002_bib0024","doi-asserted-by":"crossref","first-page":"119-124 e4","DOI":"10.1016\/j.clml.2020.11.022","article-title":"Evaluating the treatment patterns of chlormethine\/mechlorethamine gel in patients with stage I-IIA mycosis fungoides: by-time reanalysis of a randomized controlled phase 2 study","volume":"21","author":"Geskin","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.02.002_bib0025","article-title":"A little experience goes a long way: chlormethine\/mechlorethamine treatment duration as a function of clinician-level patient volume for mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL)-a retrospective cohort study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clml.2022.02.002_bib0026","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1046\/j.1523-1747.1998.00206.x","article-title":"The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma","volume":"110","author":"Vonderheid","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2022.02.002_bib0027","first-page":"1","article-title":"Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine\/mechlorethamine gel in patients with stage IA-IIA mycosis fungoides","author":"Querfeld","year":"2021","journal-title":"Dermatology"},{"key":"10.1016\/j.clml.2022.02.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100069","article-title":"Increased chlormethine-induced DNA double-stranded breaks in malignant T cells from mycosis fungoides skin lesions","volume":"2","author":"Chang","year":"2022","journal-title":"JID Innov"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502200060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502200060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:58Z","timestamp":1761871258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502200060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S215226502200060X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.02.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to Chlormethine\/Mechlorethamine gel Maintenance Treatment Regimen in Patients With Mycosis Fungoides: A Single-center Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}